Navigation Links
Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy
Date:4/6/2017

DUBLIN, April 6, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will join the Company as Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017.  In this role, Ms. Karydas will lead the Company's engagement with the investment community, and will work with the Company's Executive Leadership Team to develop and execute the Company's long-term business strategy. Ms. Karydas will report to Tessa Hilado, Chief Financial Officer of Allergan.

"I am delighted to name Daphne to this new role and excited to work with her to continue to enhance our relationships with the investment community, while simultaneously focusing on our long-term growth strategy," said Hilado. "Daphne's outstanding reputation and strong relationships across the financial community coupled with her deep healthcare and industry knowledge provides an excellent fit for this newly created role. She will be a vital leader for our organization as Allergan continues to deliver short- and long-term growth for our shareholders."

"Daphne brings to our team a tremendous mix of financial, healthcare and biopharma industry leadership. She also brings an outstanding perspective on industry and macroeconomic trends that provide the fire power necessary to identify and set strategic objectives that enhance our Growth Pharma leadership position," said Brent Saunders, Chairman and Chief Executive Officer of Allergan. "I am excited to work with Daphne as we continue building the most dynamic Company in the biopharmaceutical industry."

Ms. Karydas has more than 16 years of industry experience as a leading institutional investor and financial analyst in the biopharmaceutical sector, most recently at J.P. Morgan Asset Management. Previously, she was a healthcare Equity Research Analyst and Portfolio Manager at The Boston Company Asset Management, a Bank of New York Mellon company. Before joining The Boston Company, Ms. Karydas was a Vice President at Goldman Sachs where she worked in the Investment Banking Division as well as Goldman Sachs Asset Management focused on healthcare companies. Earlier in her career, she was a Project Chemical Engineer at Merck & Co. in the Vaccines division where she focused on process development for novel vaccines.

Ms. Karydas holds a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices, surgical and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Allergan:
Investors:  
Karina Calzadilla
(862) 261-7328

Media:
Mark Marmur
(862) 261-7558

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-names-daphne-karydas-as-senior-vice-president-of-global-investor-relations--strategy-300435866.html


'/>"/>
SOURCE Allergan plc
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg
2. Apollo Endosurgery Announces Acquisition of Obesity Intervention Division from Allergan, Inc.
3. Apollo Endosurgery Completes Acquisition of Allergan Inc.s Obesity Intervention Division
4. Increasing Use of Allergans Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
5. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
6. Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan
7. Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergans False and Misleading Statements
8. Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergans False And Misleading Statements
9. Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
10. Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders
11. Valeant Extends Offer To Acquire Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):